Covered recipient · General Payments record
CHARLES D DILLON
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,380.53
- Reported across 120 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $417.11 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $97.08 | 4 |
| Lilly USA, LLC | $65.99 | 3 |
| PFIZER INC. | $50.34 | 2 |
| Amneal Pharmaceuticals LLC | $48.54 | 2 |
| Exact Sciences Corporation | $46.94 | 2 |
| Cleerly, Inc. | $44.53 | 1 |
| ABBVIE INC. | $22.37 | 1 |
| Astellas Pharma US Inc | $21.11 | 1 |
| Janssen Pharmaceuticals, Inc | $20.21 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.37 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103642726 | CMS |
| Amneal Pharmaceuticals LLC | $24.43 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139184102 | CMS |
| Amneal Pharmaceuticals LLC | $24.11 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139184104 | CMS |
| Astellas Pharma US Inc | $21.11 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139427736 | CMS |
| Cleerly, Inc. | $44.53 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144711226 | CMS |
| Exact Sciences Corporation | $27.95 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114637346 | CMS |
| Exact Sciences Corporation | $18.99 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114637351 | CMS |
| Janssen Pharmaceuticals, Inc | $20.21 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078003440 | CMS |
| Lilly USA, LLC | $24.50 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136093973 | CMS |
| Lilly USA, LLC | $16.54 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136092688 | CMS |
| Lilly USA, LLC | $24.95 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136101268 | CMS |
| Novo Nordisk Inc | $20.01 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097263477 | CMS |
| Novo Nordisk Inc | $24.15 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096899264 | CMS |
| Novo Nordisk Inc | $26.32 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096579947 | CMS |
| Novo Nordisk Inc | $26.60 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096917570 | CMS |
| PFIZER INC. | $23.53 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131694907 | CMS |
| PFIZER INC. | $26.81 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131850767 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.